3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Breast Neoplasms
5
Multiple Myeloma
2
Lymphoma
2
Hematologic Neoplasms
2
Colorectal Neoplasms
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Thyroid Neoplasms
1
Stomach Neoplasms
1
Solid Tumors
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Pathologic Complete Response
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Neoplasm, Residual
1
Neoplasm Metastasis
1
Melanoma
1
Lung Neoplasms
1
Hemangiosarcoma
1
HER2-positive Metastatic Breast Cancer
1
HER2-Positive Primary Breast Cancer
1
Glioma
1
Esophageal Neoplasms
1
Endometrial Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Renal Cell
1
Interventions
X-Rays
6
Temozolomide
6
Specimen Handling
6
Nuclear Medicine Department, Hospital
6
Magnetic Resonance Spectroscopy
6
Biopsy
6
Phantoms, Imaging
5
Irinotecan
4
Cyclophosphamide
4
dinutuximab
3
ulixertinib
2
tipifarnib
2
selpercatinib
2
olaparib
2
larotrectinib
2
ivosidenib
2
fludarabine phosphate
2
erdafitinib
2
ensartinib
2
Topotecan
2
trametinib
1
tazemetostat
1
talazoparib
1
saponin QA-21V1
1
palbociclib
1
lutetium Lu 177 dotatate
1
irinotecan sucrosofate
1
fludarabine
1
dabrafenib
1
Vincristine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Neuroblastoma
×
Ado-Trastuzumab Emtansine
×
30 days
×
Clear all
No trials found.